SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TO ANTI-TNF THERAPY: 52-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL WITH SUBCUTANEOUS DOSING

被引：0
|
作者：
Hall, Stephen [1 ]
Kavanaugh, Arthur [2 ]
McInnes, Iain [3 ]
Mease, Philip [4 ]
Chinoy, Hector [5 ]
Kivitz, Alan [6 ]
Patekar, Manmath [7 ]
Wang, Z. [8 ]
Mpofu, Shephard [9 ]
机构：
[1] Monash Univ, Melbourne, Vic 3004, Australia
[2] Univ Calif San Diego, Sch Med, San Diego, CA USA
[3] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland
[4] Univ Washington, Swedish Med Ctr, Seattle, WA 98195 USA
[5] Univ Manchester, Manchester M13 9PL, Lancs, England
[6] Altoona Ctr Clin Res, Duncansville, PA USA
[7] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
来源：
INTERNAL MEDICINE JOURNAL | 2016年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
ARA-P88
引用
收藏
页码：38 / 39
页数：2
相关论文
共 50 条
  • [31] Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
    Deodhar, Atul
    Helliwell, Philip S.
    Boehncke, Wolf-Henning
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Subramanian, Ramanand A.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Zhuang, Yanli
    Ritchlin, Christopher T.
    LANCET, 2020, 395 (10230): : 1115 - 1125
  • [32] BIMEKIZUMAB TREATMENT IN BIOLOGIC DMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY RESULTS FROM A PHASE 3, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY
    Ostor, Andrew
    Ritchlin, Christopher T.
    Coates, Laura C.
    McInnes, Iain B.
    Mease, Philip J.
    Merola, Joseph F.
    Tanaka, Yoshiya
    Asahina, Akihiko
    Gossec, Laure
    Gottlieb, Alice B.
    Thaci, Diamant
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Shende, Vishvesh
    Coarse, Jason
    Landewe, Robert
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 26 - 26
  • [33] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice B.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Zhuang, Yanli
    van der Heijde, Desiree
    McInnes, Iain B.
    LANCET, 2020, 395 (10230): : 1126 - 1136
  • [34] Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
    McInnes, I.
    Sieper, J.
    Braun, J.
    Emery, Paul
    van der Heijde, D.
    Isaacs, J.
    Dahmen, G.
    Wollenhaupt, J.
    Schulze-Koops, H.
    Gsteiger, S.
    Bertolino, A.
    Hueber, W.
    Tak, P. P.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S306 - S306
  • [35] SECUKINUMAB, A MONOCLONAL ANTIBODY TO INTERLEUKIN-17A, SIGNIFICANTLY IMPROVES SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF A 52-WEEK PHASE 3 RANDOMIZED PLACEBO-CONTROLLED TRIAL WITH INTRAVENOUS LOADING AND SUBCUTANEOUS MAINTENANCE DOSING
    Collins, A.
    Baeten, D.
    Braun, J.
    Baraliakos, X.
    Sieper, J.
    Dougados, M.
    Emery, P.
    Deodhar, A.
    Porter, B.
    Martin, R.
    Mpofu, S.
    Richards, H.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 41 - 41
  • [36] Efficacy and Safety of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study
    Aletaha, Daniel
    Bingham, Clifton, III
    Tanaka, Yoshiya
    Agarwal, Prasheen
    Kurrasch, Regina
    Tak, Paul-Peter
    Popik, Sharon
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [37] Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study
    Aletaha, Daniel
    Bingham, Clifton O., III
    Tanaka, Yoshiya
    Agarwal, Prasheen
    Kurrasch, Regina
    Tak, Paul P.
    Popik, Sharon
    LANCET, 2017, 389 (10075): : 1206 - 1217
  • [38] SECUKINUMAB PROVIDES RAPID AND SUSTAINED REDUCTIONS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DATA FROM THE PHASE 3 RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED FUTURE 2 STUDY
    Kirkham, B.
    Mease, P.
    McInnes, I.
    Bhosekar, V.
    Mpofu, S.
    Gandhi, K.
    Gaillez, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 599 - 600
  • [39] Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing.
    Baeten, Dominique L.
    Braun, Juergen
    Baraliakos, Xenofon
    Sieper, Joachim
    Dougados, Maxime
    Emery, Paul
    Deodhar, Atul A.
    Porter, Brian
    Martin, Ruvie
    Mpofu, Shephard
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S360 - S360
  • [40] EFFICACY OF GOLIMUMAB, A HUMAN ANTI-TNFα ANTIBODY, BY BASELINE CRP LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THREE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
    Emery, Paul
    Genovese, Mark C.
    Fleischmann, Roy M.
    Matteson, Eric L.
    Hsia, Elizabeth C.
    Xu, Stephen
    Doyle, Mittie K.
    Rahman, Mahboob U.
    RHEUMATOLOGY, 2010, 49 : I101 - I101
12345